A Phase 3 interventional study of Lurasidone in Schizophrenia and Bipolar Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 46 sites in 12 countries. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 19th largest by enrollment, is one of 3 that started in 2011, is one of 18 in phase 3, and was the 18th registered.
3,567 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
This study's enrollment of 162 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 22nd largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2011, is one of 21 in phase 3, and was the 19th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone flexibly dosed
Drug: Lurasidone
Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs
Primary Safety assessments included spontaneous adverse event (AE) and serious adverse events (SAEs) monitoring.
Time frame: 18 months
Change From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
Time frame: 18 months
| Milestone | Lurasidone |
|---|---|
| Started | 162 |
| Completed | 40 |
| Not completed | 122 |
| Withdrew: Adverse event | 10 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Terminated by sponsor | 95 |
Primary Safety assessments included spontaneous adverse event (AE) and serious adverse events (SAEs) monitoring.
| participants | Lurasidone |
|---|---|
| Subject with at least on treatment emergent AE | 63 |
| Subject with at least one treatment emergent SAE | 7 |
| Subjects discontinued due to TEAE | 10 |
The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone |
|---|---|
| Change From Baseline to Month 18 (LOCF) in the Clinical Global Impression Severity Score (CGI-S | -0.18 ± 0.877 |
Collected over 18 Months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 7/162 (4.3%) | 40/162 (24.7%) |
| Event | Lurasidone |
|---|---|
| ManiaPsychiatric disorders | 2/162 |
| Pilonidal cystInfections and infestations | 1/162 |
| Foot fractureInjury, poisoning and procedural complications | 1/162 |
| DepressionPsychiatric disorders | 1/162 |
| Depression suicidalPsychiatric disorders | 1/162 |
| Schizophrenia, paranoid typePsychiatric disorders | 1/162 |
| Event | Lurasidone |
|---|---|
| HeadacheNervous system disorders | 9/162 |
| DiarrhoeaGastrointestinal disorders | 6/162 |
| InfluenzaInfections and infestations | 6/162 |
| NasopharyngitisInfections and infestations | 6/162 |
| VomitingGastrointestinal disorders | 5/162 |
| AnxietyPsychiatric disorders | 5/162 |
| InsomniaPsychiatric disorders | 5/162 |
| NauseaGastrointestinal disorders | 4/162 |
| Viral upper respiratory tract infectionInfections and infestations | 4/162 |
| Hepatic enzyme increaseInvestigations | 4/162 |
| Age, Categorical(Participants) | Lurasidone |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 159 |
| >=65 years | 2 |
| Age, Continuous(years) | Lurasidone |
|---|---|
| Mean | 41.3 ± 12.08 |
| Sex: Female, Male(Participants) | Lurasidone |
|---|---|
| Female | 77 |
| Male | 85 |
| Race (NIH/OMB)(Participants) | Lurasidone |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 32 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 105 |
| More than one race | 0 |
| Unknown or Not Reported | 20 |
| Region of Enrollment(participants) | Lurasidone |
|---|---|
| Serbia | 6 |
| France | 6 |
| Czech Republic | 25 |
| Slovakia | 17 |
| Canada | 3 |
| Ukraine | 11 |
| Romania | 2 |
| Lithuania | 8 |
| Russian Federation | 20 |
| South Africa | 26 |
| Colombia | 6 |
| India | 32 |
The record gives a start of Jun 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →